Canopy Biosciences

About

Canopy Biosciences aims to accelerate the commercialization of life science reagent tools and services through in-licensing.

St Louis,Missouri,United States
11 - 50

Highlights

Details

Last Funding Type: Series A
Last Funding Money Raised: $2.40M
Industries: Biopharma,Biotechnology,Health Care,Life Science
Founded date: Jan 1, 2016
Number Of Employee: 11 - 50
Operating Status: Active

Canopy Biosciences is biotechnological company that provides products and services for gene editing and personalized medicine. The gene editing technology is called TUNR and targets translation elongation by inserting polyA tracks into targeted coding regions of the genome. This change then decreases the levels of mRNA transcribed from the gene and therefore suppresses protein expression. It was initially developed by Professor Sergej Djuranovic at Washington University School of Medicine and Professor Rachel Green from Johns Hopkins University.

Canopy Biosciences was formed in 2016 and is headquartered in Saint Louis, Missouri.

Funding Rounds

Number of Funding Rounds

Total Funding Amount

3

$4.40M

Canopy Biosciences has raised a total of $4.40M in funding over 2 rounds. Their latest funding was raised on Apr 30, 2019 from a Series Unknown round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
Apr 30, 2019	Series Unknown	—	1	—	—	Detail
May 22, 2018	Series A	$2.40M	6	BioGenerator Kingdom Capital	—	Detail
Jan 30, 2017	Seed	$2M	1	—	—	Detail

Investors

Number of Lead Investors

Number of Investors

2

7

Canopy Biosciences is funded by 7 investors. BioGenerator and Kingdom Capital are the most recent investors.

Investor Name	Lead Investor	Funding Round
BioGenerator	Yes	Series A
Kingdom Capital	Yes	Series A
Ampersand Capital Partners	—	Series Unknown
Greenleaf Seed Fund	—	Series A
Archangels	—	Series A
Missouri Technology Corporation	—	Series A
Pinpoint Holdings	—	Series A